نتایج جستجو برای: transient hyperammonemia

تعداد نتایج: 128011  

2015
M. Stuy G.-F. Chen J.M. Masonek B.F. Scharschmidt

A severely chronically protein and calorie restricted young woman with argininosuccinate lyase deficiency developed transient refeeding syndrome (RFS) and hyperammonemia after modest diet liberalization following initiation of glycerol phenylbutyrate (GPB). The patient required IV supportive care and supplementation with potassium, magnesium and calcium. She is now doing well on GPB and an appr...

2014
Yu-Lung Tseng Chi-Ren Huang Chih-Hsiang Lin Yan-Ting Lu Cheng-Hsien Lu Nai-Ching Chen Chiung-Chih Chang Wen-Neng Chang Yao-Chung Chuang Peter Mclaughlin

Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy. This study aimed to determine the risk factors for hyperammonemia in patients with epilepsy treated with VPA. One hundred and fifty-eight adult patients with epilepsy aged older than 17 years who received VPA therapy were enrolled into this study. Blood samples were taken during the interict...

2018
Yuya Nakamura Isao Ohsawa Yoshikazu Goto Hiromichi Gotoh

Gastrorenal shunts may induce hyperammonemia. Portosystemic shunts should be suspected when hyperammonemia occurs in patients with chronic kidney disease.

Journal: :Proceedings 2015
Chibuzo Clement Odigwe Binod Khatiwada Christopher Holbrook Ifeoma Sylvia Ekeh Chukwuemeka Uzoka Isaac Ikwu Bishwas Upadhyay

Hyperammonemia is a recognized cause of encephalopathy. However, it is commonly seen in patients with liver disease. The clinical entity of noncirrhotic hyperammonemia is now being increasingly recognized. We report a man who presented to our hospital with relapsing altered mental status later diagnosed as noncirrhotic hyperammonemia.

2016
Keiki Nagaharu Kenji Ikemura Yoshiki Yamashita Hiroyasu Oda Mikiya Ishihara Yumiko Sugawara Satoshi Tamaru Toshiro Mizuno Naoyuki Katayama

Over the past decades, 5-Fluorouracil (5-FU) has been widely used to treat several types of carcinoma, including esophageal squamous cell carcinoma. In addition to its common side effects, including diarrhea, mucositis, neutropenia, and anemia, 5-FU treatment has also been reported to cause hyperammonemia. However, the exact mechanism responsible for 5-FU-induced hyperammonemia remains unknown....

2016
Ruby Upadhyay Thomas P Bleck Katharina M Busl

Purpose. A 66-year-old man who presented with coma was found to have isolated severe hyperammonemia and diagnosed with a late-onset urea-cycle disorder. He was treated successfully and had full recovery. Methods. We report a novel case of noncirrhotic hyperammonemia and review the literature on this topic. Selected literature for review included English-language articles concerning hyperammonem...

Journal: :Therapeutics and clinical risk management 2016
Majid Alfadhel Fuad Al Mutairi Nawal Makhseed Fatma Al Jasmi Khalid Al-Thihli Emtithal Al-Jishi Moeenaldeen AlSayed Zuhair N Al-Hassnan Fathiya Al-Murshedi Johannes Häberle Tawfeg Ben-Omran

BACKGROUND Hyperammonemia is a life-threatening event that can occur at any age. If treated, the early symptoms in all age groups could be reversible. If untreated, hyperammonemia could be toxic and cause irreversible brain damage to the developing brain. OBJECTIVE There are major challenges that worsen the outcome of hyperammonemic individuals in the Middle East. These include: lack of aware...

2018
Jing Liu Enkhchimeg Lkhagva Hea-Jong Chung Hyeon-Jin Kim Seong-Tshool Hong

Ammonia is constantly produced as a metabolic waste from amino acid catabolism in mammals. Ammonia, the toxic waste metabolite, is resolved in the liver where the urea cycle converts free ammonia to urea. Liver malfunctions cause hyperammonemia that leads to central nervous system (CNS) dysfunctions, such as brain edema, convulsions, and coma. The current treatments for hyperammonemia, such as ...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2013
Jia Qiu Samjhana Thapaliya Ashok Runkana Yu Yang Cynthia Tsien Maradumane L Mohan Arvind Narayanan Bijan Eghtesad Paul E Mozdziak Christine McDonald George R Stark Stephen Welle Sathyamangla V Naga Prasad Srinivasan Dasarathy

Loss of muscle mass, or sarcopenia, is nearly universal in cirrhosis and adversely affects patient outcome. The underlying cross-talk between the liver and skeletal muscle mediating sarcopenia is not well understood. Hyperammonemia is a consistent abnormality in cirrhosis due to impaired hepatic detoxification to urea. We observed elevated levels of ammonia in both plasma samples and skeletal m...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید